RayzeBio Inc., a San Diego-based company that is building a large factory on the northwest side of Indianapolis to make radioisotopes for cancer treatment, has agreed to be acquired by pharmaceutical company Bristol Myers Squibb for $4.1 billion.... Read More
In its latest push into artificial intelligence, Lilly has signed a deal with a California-based biotech to discover new obesity targets in humans. Fauna Bio says it will give Lilly access to its AI platform to support preclinical drug discovery efforts.... Read More
Novartis says its $100 million cutting-edge Indianapolis facility to manufacture the new nuclear medicine Pluvicto is on the cusp of opening—and the drug’s genesis belongs to Purdue University’s Dr. Philip Low, a serial entrepreneur and industry icon. ... Read More
The OrthoPediatrics Specialty Bracing division will develop new products for the company and is expect to grow its total addressable market by about $600 million.... Read More
A South Bend-based startup is one step closer to market with a device for heart failure patients that—tucked under their home mattress—monitors the body for a common complication: fluid overload. ... Read More
Suddenly, Eli Lilly and Co. has a new potential competitor in the lucrative market for obesity drugs. Roche AG, the health care giant based in Basel, Switzerland, says is acquiring a California-based biotech that is developing obesity drugs for $2.7 billion.... Read More
West Lafayette-based startup founded by Indiana life sciences icon Dr. Philip Low has secured $30 million in funding. On Target Laboratories plans to use the funding to accelerate commercialization of Cytalux, used to illuminate cancer cells during surgery.... Read More
Eli Lilly and Co. is making a mark on helping millions of people lose weight with the recent approval from the U.S. Food and Drug Administration for its weight loss drug, Zepbound. The approval is drumming up excitement among doctors and patients. ... Read More
Warsaw-based Precision Medical Technologies is rebranding to better reflect what it says is its adaptability of services and products. The contract manufacturer of orthopedic implants and devices said Thursday the effort includes a new logo and name branding.... Read More
On the doorstep of testing with a state police department, Peter Zahrt says he’s hopeful the fundraising will soon be in place to manufacture the device for the 10 police departments—some in Indiana—already in line to purchase it.... Read More
The CEO of Indianapolis-based Eli Lilly and Co. says it's "a historic time at the old pill company on the south side of the city" after receiving regulatory approval for the company's highly anticipated injectable weight loss drug, Zepbound.... Read More
Two Notre Dame professors received cash prizes in the 1st Source Bank Commercialization Awards. The awards are given to to faculty from Notre Dame or IU South Bend who have "successfully transitioned their technologies from the lab to the marketplace."... Read More
Warsaw-based not-for-profit OrthoWorx and Warsaw Community Schools are teaming up for an initiative to give high school students the opportunity to prepare for careers in the orthopedic manufacturing industry.... Read More
One of Bloomington’s largest employers is now under new ownership, following the decision by Baxter International to sell its biopharma operations to a new company backed by private-equity and investment firms.... Read More
Eleftherios Garyfallidis recently received the grant from the National Institutes of Health's BRAIN 2.0 Initiative, which seeks to advance open-source software for neuroanatomy.... Read More
Eli Lilly and Co. announced Friday morning it plans to build a $2.5 billion factory in Germany to make injectable drugs, its latest move to meet the soaring demand for its medicines for diabetes and weight loss.... Read More
Two Indiana companies have been named to Deloitte's 2023 Technology Fast 500 list. Deloitte uses the annual honors to recognize the fastest-growing North American companies in the tech, media, telecommunications, life sciences, fintech and energy tech sectors.... Read More
Lamb is the executive director of the IU School of Medicine's Stark Neurosciences Research Institute and co-directs the Neurosciences Institute.... Read More
Fishers-based gene therapy firm Genezen has closed on a $18.5 million growth equity investment led by Boston-based Ampersand Capital Partners. The company said Thursday it will use the funding to accelerate expansion plans at its Fishers headquarters.... Read More
Excluding nonrecurring items, the Indianapolis-based drugmaker posted adjusted earnings of 10 cents a share, beating Zacks consensus estimate of a loss of 11 cents a share.... Read More
